Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...

(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...

RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination ...

TEL-AVIV, Israel and RALEIGH, N.C. - RedHill Biopharma Ltd. (NASDAQ: NASDAQ:RDHL), a specialty biopharmaceutical company with a market capitalization of $7.53 million, today announced the initiation ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the coverage of Talicia by Humana's Part D Plan, providing access to ...

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

Stock analysts at StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a research note issued to investors on Friday. The firm set a “hold” rating on the ...

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial ...

Supreme Court Of New York Awards RedHill Biopharma Approx. $8 Million Plus Costs In Breach Of Contract Lawsuit ...

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...